Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a reversal drug wake up ICU patients faster after a breathing tube?

NCT ID NCT05993390

Knowledge-focused Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a drug to reverse muscle relaxants after placing a breathing tube helps doctors check brain function sooner. Thirty critically ill adults in the ICU will receive either sugammadex, neostigmine, or no reversal drug. Researchers will measure how quickly patients can open their eyes or move on command.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sugammadex and neostigmine
What this could lead to
If it works, this could help doctors assess brain function faster in critically ill patients after intubation.
What could go wrong
This is a very small early-phase study with only 30 participants, so results may not apply broadly. The drugs themselves carry risks like allergic reactions or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 19 years of age or older who were intubated after admission to the intensive care unit. Exclusion Criteria: * Patients younger than 19 years of age * Patients who are not neurologically evaluable or have concomitant neurologic dysfunction * Patients with neuromuscular disorder * Patients with a history of drug allergic reactions to sugammadex or neostigmine * Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness Neurologic Manifestations

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Neurologic findings Neuromuscular blockade

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Seoul National University Hospital

    RECRUITING

    Seoul, Jongno-gu, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.